Treatment
Axitinib clinical trials
We’re tracking 27 recruiting studies that include Axitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT07235085RecruitingPhase 3
Study of OTX-TKI implant for moderate to severe NPDR
This study tests an eye implant (OTX-TKI) that slowly releases a medicine to slow or stop worsening of non-proliferative diabetic retinopathy (NPDR) — an early form of diabetic eye disease. It's for people with moderately severe to severe NPDR who haven't had significant treatments like laser or injections in that eye.
Hagerstown, MarylandAges 18 years+ - NCT07469683RecruitingPhase 2
Combination therapy for advanced kidney cancer after first-line treatment
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
SeoulAges 19 years+ - NCT06424626Enrolling by invitationPhase 1
Testing new drug combos for advanced mucosal melanoma
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
BeijingAges 18 years+ - NCT07123090RecruitingPhase 2
Triple Therapy for Advanced Kidney Cancer
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05384496RecruitingPhase 2
Axitinib and nivolumab for advanced mucosal melanoma
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
Harrison, New YorkAges 18 years+ - NCT05096390RecruitingPhase 2
Axitinib plus pembrolizumab for first metastatic kidney cancer
This Phase 2 trial studies whether combining axitinib and pembrolizumab can shrink and control metastatic or inoperable type 2 or mixed papillary kidney cancer. It may help by blocking cancer growth signals and boosting the immune system to attack the cancer.
AngersAges 18 years+ - NCT07744932RecruitingPhase 2
Radiation plus drug combo for kidney cancer that has spread a little
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
Shijiazhuang, HebeiAges 18 years+ - NCT06889649RecruitingPhase 2
SBRT plus immunotherapy and targeted therapy for kidney cancer
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT05738694RecruitingPhase 3
Test axitinib plus immunotherapy before kidney cancer surgery
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
BeijingAges 18–80 - NCT05817903RecruitingPhase 2
Nivolumab with or without axitinib after prior nivolumab
This Phase 2 trial studies whether adding axitinib to nivolumab (or giving nivolumab alone) can better control advanced clear-cell kidney cancer after standard initial treatment with nivolumab plus ipilimumab. It may help by extending response or slowing tumor growth while improving how long treatment works.
BresciaAges 18 years+ - NCT05969496RecruitingPhase 2
Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Aurora, ColoradoAges 18 years+ - NCT06211114RecruitingPhase 2
Immunotherapy and targeted drug for advanced collecting duct kidney cancer
This trial tests a combination of immunotherapy and a targeted drug (axitinib) for people with advanced collecting duct carcinoma, a rare type of kidney cancer. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT07172386RecruitingPhase 2
Pre-surgery treatment for advanced kidney cancer
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Bakersfield, CaliforniaAges 50 years+ - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT04341181RecruitingPhase 2
Targeted cancer treatment chosen by tumor genetic test results
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
Aalborg, AalborgAges 18 years+ - NCT05287464Recruiting
Study for metastatic kidney cancer treatments combinations
This trial studies people with advanced (metastatic) kidney cancer who are starting a specific set of first-line treatment combinations (including drugs like nivolumab, pembrolizumab, or avelumab, paired with targeted medicines). It may help improve how these treatment plans work for different types of kidney cancer.
Province of Macerata, MacerataAges 18 years+ - NCT05327686RecruitingPhase 2
Adding focused radiation to immunotherapy for kidney cancer
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Birmingham, AlabamaAges 18 years+ - NCT06364631RecruitingPhase 3
Testing a new approach for advanced kidney cancer
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
ViennaAges 18 years+ - NCT06690697RecruitingPhase 2
Toripalimab and JS004 for advanced kidney cancer
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07227415RecruitingPhase 1/Phase 2
Study of a new drug for advanced kidney cancer
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT06726421RecruitingPhase 3
Systemic therapy with or without radiation for kidney cancer that has spread to a few spots
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
Fuzhou, FujianAges 18 years+
What Axitinib is being studied for
Conditions with recruiting Axitinib studies.
Common questions
- Are there clinical trials studying Axitinib?
- Yes. Clin2 currently lists 27 recruiting studies that include Axitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Axitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Axitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Axitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.